Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success

Z. Ušiaková, V. Mikulová, D. Pintérová, M. Brychta, J. Valchář, M. Kubecová, P. Tesařová, V. Bobek, K. Kološtová,

. 2014 ; 28 (4) : 605-14.

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15014176

UNLABELLED: Circulating tumor cells (CTCs) are an independent prognostic factor for patients with metastatic breast cancer (MBC). However, the role of CTCs in early breast cancer management is not yet clearly defined. The aim of this study was to assess the CTC-positivity rate in patients undergoing chemotherapy depending on breast cancer stage in the adjuvant and neoadjuvant setting. We evaluated the ability to confirm therapy response by CTC analysis. PATIENTS AND METHODS: CTCs isolated from blood by means of immunomagnetic separation were further characterized by means of reverse transcriptase - polymerase chain reaction (RT-PCR) for epithelial cell adhesion molecule (EPCAM), mucin 1 (MUC1) and v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (HER2) transcripts with the AdnaTest™. This prospective study included 179 patients; altogether 419 blood samples were evaluated. Patients with primary tumors were divided into neoadjuvant (n=38), and adjuvant (n=100) groups. Forty-one patients with MBC were evaluated under palliative treatment. RESULTS: CTC positivity was described in 35% of patients with early breast cancer without detected metastases before neoadjuvant chemotherapy; similarly, a 26% positivity rate was found in the adjuvant group. In patients with MBC, we detected CTCs in 43% of them. After completing the therapy, the CTC positivity rate decreased to 5% in the neoadjuvant group, to 13% in the adjuvant group and to 12% in the MBC group. CTC positivity after the therapy may classify a subgroup of patients at high risk of developing metastatic disease. This was even true when a patient was evaluated as being CTC-negative before chemotherapy. The multivariate analysis evaluating the correlation of CTC positivity with clinicopathological characteristics such as tumor size, nodal involvement, hormone receptor status, HER2 expression and number of metastatic sites revealed no statistically significant relationships. CONCLUSION: CTC status may have a significant impact on early BC management.

000      
00000naa a2200000 a 4500
001      
bmc15014176
003      
CZ-PrNML
005      
20180611104450.0
007      
ta
008      
150420s2014 gr f 000 0|eng||
009      
AR
035    __
$a (PubMed)24982230
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Bielčíková, Zuzana $u Oncology Clinic, Third Faculty of Medicine, Charles University, Prague, Czech Republic. $7 xx0225233
245    10
$a Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success / $c Z. Ušiaková, V. Mikulová, D. Pintérová, M. Brychta, J. Valchář, M. Kubecová, P. Tesařová, V. Bobek, K. Kološtová,
520    9_
$a UNLABELLED: Circulating tumor cells (CTCs) are an independent prognostic factor for patients with metastatic breast cancer (MBC). However, the role of CTCs in early breast cancer management is not yet clearly defined. The aim of this study was to assess the CTC-positivity rate in patients undergoing chemotherapy depending on breast cancer stage in the adjuvant and neoadjuvant setting. We evaluated the ability to confirm therapy response by CTC analysis. PATIENTS AND METHODS: CTCs isolated from blood by means of immunomagnetic separation were further characterized by means of reverse transcriptase - polymerase chain reaction (RT-PCR) for epithelial cell adhesion molecule (EPCAM), mucin 1 (MUC1) and v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (HER2) transcripts with the AdnaTest™. This prospective study included 179 patients; altogether 419 blood samples were evaluated. Patients with primary tumors were divided into neoadjuvant (n=38), and adjuvant (n=100) groups. Forty-one patients with MBC were evaluated under palliative treatment. RESULTS: CTC positivity was described in 35% of patients with early breast cancer without detected metastases before neoadjuvant chemotherapy; similarly, a 26% positivity rate was found in the adjuvant group. In patients with MBC, we detected CTCs in 43% of them. After completing the therapy, the CTC positivity rate decreased to 5% in the neoadjuvant group, to 13% in the adjuvant group and to 12% in the MBC group. CTC positivity after the therapy may classify a subgroup of patients at high risk of developing metastatic disease. This was even true when a patient was evaluated as being CTC-negative before chemotherapy. The multivariate analysis evaluating the correlation of CTC positivity with clinicopathological characteristics such as tumor size, nodal involvement, hormone receptor status, HER2 expression and number of metastatic sites revealed no statistically significant relationships. CONCLUSION: CTC status may have a significant impact on early BC management.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a nádory prsu $x diagnóza $x genetika $x patologie $x terapie $7 D001943
650    _2
$a nádory prsu u mužů $x diagnóza $x genetika $x patologie $x terapie $7 D018567
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a stupeň nádoru $7 D060787
650    _2
$a staging nádorů $7 D009367
650    _2
$a nádorové cirkulující buňky $x metabolismus $x patologie $7 D009360
650    _2
$a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
650    _2
$a senzitivita a specificita $7 D012680
650    _2
$a tumor burden $7 D047368
650    _2
$a nádorové biomarkery $x genetika $x metabolismus $7 D014408
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Mikulová, Veronika $u Institute of Clinical Biochemistry, Allergology and Immunology, General Faculty Hospital, First Faculty of Medicine, Third Faculty of Medicine, Charles University, Prague, Czech Republic. $7 xx0208972
700    1_
$a Pintérová, Daniela $u Department of Tumor Biology, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Brychta, Milan $u Radiotherapy and Oncology Clinic, Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Valchář, Josef $u Radiotherapy and Oncology Clinic, Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Kubecová, Martina $u Radiotherapy and Oncology Clinic, Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Tesařová, Petra $u Oncology Clinic, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Bobek, Vladimír $u Department of Laboratory Genetics, Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland.
700    1_
$a Kološtová, Katarína $u Department of Tumor Biology, Third Faculty of Medicine, Charles University, Prague, Czech Republic katarina.kolostova@gmail.com.
773    0_
$w MED00175831 $t In vivo (Athens, Greece) $x 1791-7549 $g Roč. 28, č. 4 (2014), s. 605-14
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24982230 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150420 $b ABA008
991    __
$a 20180611104701 $b ABA008
999    __
$a ok $b bmc $g 1071757 $s 897054
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 28 $c 4 $d 605-14 $i 1791-7549 $m In Vivo $n In Vivo $x MED00175831
LZP    __
$a Pubmed-20150420

Najít záznam

Citační ukazatele

Možnosti archivace